New prostate cancer marker helps identify men whose cancer is likely to spread

October 03, 2006

Prostate cancer researchers at Sydney's Garvan Institute, supported by the Cancer Institute NSW, have found a new marker for identifying aggressive prostate cancers.

Many men with prostate cancer have their prostate glands removed, but only a proportion of these men will later develop life-threatening metastatic disease - where the cancer spreads to other parts of the body such as the bones. This new marker can identify which men are at the highest risk of metastatic disease at the time of their initial surgery leading to tailored treatment for individual prostate cancer sufferers, something that is not currently possible.

A/Prof Sue Henshall, who leads the prostate cancer research group, says: "We have discovered that men who have low levels of a marker called AZGP1 in the prostate at the time of surgery, have a greatly increased risk of developing metastatic cancer. This means two things: that these men could benefit from more aggressive treatment such as radiotherapy or chemotherapy around the time of surgery when they still have potentially curable cancer; and that patients with a low risk of developing metastatic disease will have the option of deferring treatments that have a negative impact on quality of life."

The next step is to explore the relationship between low levels of AZGP1 and the development of metastatic cancer in other groups of men with prostate cancer (i.e. other prostate cancer tissue banks). "It is important to begin testing for this marker now because in the next decade, when the outcomes for some of these new patients is known, we will be able to see just how predictive our marker is in the clinic", said Garvan's Cancer Program Director Professor Rob Sutherland.

"A/Prof Sue Henshall's research has put Australia at the forefront of world research in developing efficient prognostic tools in prostate cancer," said Prof Jim Bishop, Chief Cancer Officer NSW and CEO of Cancer Institute NSW, which funded the research as part of a $3.7 million Program Grant for Excellence in Translational Research.
Notes for editors:
This research is published in the current edition of the prestigious US publication, the Journal of the National Cancer Institute, which is the most cited cancer research journal.

This work was the result of a $3.7 million Program Grant from the Cancer Institute NSW to identify risk in prostate cancer. Authors A/Prof Sue Henshall and Dr Andrew Biankin are Career Development and Support Fellows of the Cancer Institute NSW. The Cancer Institute NSW is funded by the NSW State Government. It is a statutory body governed by the Cancer Institute NSW Board appointed by the Minister for Health, the Hon. John Hatzistergos MLC. and the Minister Assisting the Minister for Health (Cancer), the Hon. Frank Sartor, MP.

Zinc-alpha2-glycoprotein Expression as a Predictor of Metastatic Prostate Cancer Following Radical Prostatectomy. Susan M. Henshall, Lisa G. Horvath, David I. Quinn, Sarah A. Eggleton, John J. Grygiel, Phillip D. Stricker, Andrew V. Biankin, James G. Kench , Robert L. Sutherland. Journal of the National Cancer Institute. Oct 4 2006.

The prostate is a walnut-sized organ that lies close to the bladder and bowel and is only found in men. Its main function is to store and produce seminal fluid. Prostate cancer is potentially curable if detected early and treated while still confined to the prostate gland.

Prostate cancer is rare before the age of 50, but most common from the age of 55, with the median age on diagnosis of prostate cancer being 71 years. It rates first in incidence and second in mortality for all male cancers.

Prostate cancer affects 13,000 men in Australia. Of these, approximately 20% of prostate cancer sufferers will develop metastatic disease within 10 years of surgery. The rate of change in PSA (prostate-specific antigen) levels is monitored for about ten years after surgery. If it increases at a rapid rate, for which there is an accepted definition, treatment with hormone depletion is likely to ensue.

The Garvan Institute of Medical Research was founded in 1963 by the Sisters of Charity. Initially a research department of St Vincent's Hospital in Sydney, it is now one of Australia's largest medical research institutions with approximately 400 scientists, students and support staff. The Garvan Institute's main research programs are: Cancer, Diabetes & Obesity, Arthritis & Immunology, Osteoporosis, and Neuroscience. It is part of the St Vincent's Hospital Campus.

All Cancer Institute NSW media enquiries should be directed to:
John Suter-Linton
Manager Communications
+61 2 8374 5709
+61 (0)422 005 928

Research Australia

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to